Shares of Ophthotech Corp. (NASDAQ:OPHT) have earned an average rating of “Buy” from the ten brokerages that are covering the stock. Two equities research analysts have rated the stock with a sell rating and eight have given a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $91.78.

OPHT has been the subject of several recent research reports. Citigroup Inc. lifted their price objective on Ophthotech Corp. from $91.00 to $92.00 and gave the company a “buy” rating in a report on Thursday, August 4th. BTIG Research restated a “buy” rating and issued a $92.00 price objective on shares of Ophthotech Corp. in a report on Monday, October 3rd. Cowen and Company set a $60.00 price objective on Ophthotech Corp. and gave the company a “buy” rating in a report on Saturday, October 1st. Chardan Capital restated a “buy” rating and issued a $200.00 price objective on shares of Ophthotech Corp. in a report on Monday, October 31st. Finally, Barclays PLC restated a “buy” rating and issued a $70.00 price objective on shares of Ophthotech Corp. in a report on Wednesday, November 9th.

Ophthotech Corp. (NASDAQ:OPHT) opened at 35.33 on Wednesday. The stock’s market cap is $1.26 billion. Ophthotech Corp. has a 12-month low of $29.85 and a 12-month high of $80.00. The company has a 50 day moving average of $37.39 and a 200-day moving average of $49.99.

Ophthotech Corp. (NASDAQ:OPHT) last released its quarterly earnings data on Tuesday, November 8th. The biopharmaceutical company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($1.64) by $0.07. The firm earned $1.67 million during the quarter, compared to the consensus estimate of $6.20 million. Ophthotech Corp. had a negative net margin of 323.19% and a negative return on equity of 916.07%. Equities analysts forecast that Ophthotech Corp. will post ($4.94) earnings per share for the current year.

In related news, CEO David R. Guyer sold 22,060 shares of the company’s stock in a transaction that occurred on Tuesday, November 1st. The stock was sold at an average price of $35.61, for a total value of $785,556.60. Following the sale, the chief executive officer now owns 24,541 shares in the company, valued at $873,905.01. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, President Samir Chandrakant Patel sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, September 29th. The shares were sold at an average price of $55.17, for a total value of $1,103,400.00. Following the completion of the sale, the president now owns 24,239 shares in the company, valued at approximately $1,337,265.63. The disclosure for this sale can be found here. Insiders own 2.00% of the company’s stock.

Large investors have recently modified their holdings of the stock. BNP Paribas Arbitrage SA raised its stake in shares of Ophthotech Corp. by 114.4% in the third quarter. BNP Paribas Arbitrage SA now owns 2,590 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 1,382 shares in the last quarter. Teacher Retirement System of Texas raised its stake in shares of Ophthotech Corp. by 18.5% in the second quarter. Teacher Retirement System of Texas now owns 3,582 shares of the biopharmaceutical company’s stock worth $183,000 after buying an additional 559 shares in the last quarter. Great West Life Assurance Co. Can raised its stake in shares of Ophthotech Corp. by 66.0% in the third quarter. Great West Life Assurance Co. Can now owns 3,651 shares of the biopharmaceutical company’s stock worth $168,000 after buying an additional 1,451 shares in the last quarter. BlackRock Inc. raised its stake in shares of Ophthotech Corp. by 138.0% in the second quarter. BlackRock Inc. now owns 3,965 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 2,299 shares in the last quarter. Finally, Emerald Acquisition Ltd. purchased a new stake in shares of Ophthotech Corp. during the second quarter worth approximately $227,000. Hedge funds and other institutional investors own 93.89% of the company’s stock.

Ophthotech Corp. Company Profile

Ophthotech Corporation is a biopharmaceutical company. The Company specializes in the development of therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (AMD). Its advanced product candidate is Fovista, which is for use in combination with anti-vascular endothelial growth factor (VEGF) drugs.

5 Day Chart for NASDAQ:OPHT

Receive News & Stock Ratings for Ophthotech Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech Corp. and related stocks with our FREE daily email newsletter.